I agree that this site is using cookies. You can find further informations here.
X
Verstovsek, S.
216  results:
Search for persons X
?
1

Immunotherapy: CXCR4 ENRICHED UMBILICAL CORD BLOOD DERIVED ..:

Huang, M. ; Zeng, K. ; Lyu, M....
Cytotherapy.  25 (2023)  6 - p. S246-S247 , 2023
Link: https://doi.org/10.1016/..
 
?
2

P1043: OUTCOME OF PATIENTS WITH PREFIBROTIC MYELOFIBROSIS F..:

Masarova, L. ; Bose, P. ; Pemmaraju, N....
HemaSphere.  6 (2022)  - p. 933-934 , 2022
Link: https://doi.org/10.1097/..
 
?
3

P1066: OUTCOMES OF COVID-19 IN PATIENTS WITH MYELOPROLIFERA..:

Venugopal, S. ; Song, H. ; Young, C....
HemaSphere.  6 (2022)  - p. 956-957 , 2022
Link: https://doi.org/10.1097/..
 
?
4

S198: BET INHIBITOR PELABRESIB (CPI-0610) COMBINED WITH RUX..:

Mascarenhas, J. ; Kremyanskaya, M. ; Patriarca, A....
HemaSphere.  6 (2022)  - p. 99-100 , 2022
Link: https://doi.org/10.1097/..
 
?
5

P1037: DOES EARLY INTERVENTION IN MYELOFIBROSIS IMPACT OUTC..:

Harrison, C. ; Kiladjian, J.-J. ; Vannucchi, A. M....
HemaSphere.  6 (2022)  - p. 927-928 , 2022
Link: https://doi.org/10.1097/..
 
?
6

P1052: IMPACT OF SF3B1 MUTATION IN MYELOFIBROSIS:

Senapati, J. ; Verstovsek, S. ; Masarova, L....
HemaSphere.  6 (2022)  - p. 942-943 , 2022
Link: https://doi.org/10.1097/..
 
?
7

P1041: IMPACT OF FEDRATINIB ON SPLEEN VOLUME AND MYELOFIBRO..:

Kiladjian, J.-J. ; Tefferi, A. ; Passamonti, F....
HemaSphere.  6 (2022)  - p. 931-932 , 2022
Link: https://doi.org/10.1097/..
 
?
8

P1029: MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF PELA..:

Gupta, V. ; Mascarenhas, J. ; Kremyanskaya, M....
HemaSphere.  6 (2022)  - p. 919-920 , 2022
Link: https://doi.org/10.1097/..
 
?
9

P1042: SAFETY AND TOLERABILITY RESULTS FROM THE PHASE 3B FR..:

Gupta, V. ; Yacoub, A. ; Verstovsek, S....
HemaSphere.  6 (2022)  - p. 932-933 , 2022
Link: https://doi.org/10.1097/..
 
?
10

P1030: MANIFEST-2, A GLOBAL, PHASE 3, RANDOMIZED, DOUBLE-BL..:

Harrison, C. ; Rampal, R. K. ; Gupta, V....
HemaSphere.  6 (2022)  - p. 920-921 , 2022
Link: https://doi.org/10.1097/..
 
?
11

P1068: RISK-ADJUSTED SAFETY ANALYSIS OF PACRITINIB IN PATIE..:

Vannucchi, A. ; Pemmaraju, N. ; Scott, B....
HemaSphere.  6 (2022)  - p. 958-959 , 2022
Link: https://doi.org/10.1097/..
 
?
12

P1028: PTG-300 (RUSFERTIDE) TREATMENT INTERRUPTION REVERSES..:

Kuykendall, A. ; Kremyanskaya, M. ; Ginsburg, Y....
HemaSphere.  6 (2022)  - p. 918-919 , 2022
Link: https://doi.org/10.1097/..
 
?
13

S192: SINGLE-CELL RNA PROFILING OF MYELOFIBROSIS PATIENTS R..:

Zavidij, O. ; Haradhvala, N. J. ; Meyer, R....
HemaSphere.  6 (2022)  - p. 93-94 , 2022
Link: https://doi.org/10.1097/..
 
?
14

P1054: MYLOX-1: AN OPEN-LABEL, PHASE IIA STUDY OF THE SAFET..:

Harrison, C. ; Mascarenhas, J. ; Rampal, R....
HemaSphere.  6 (2022)  - p. 944-945 , 2022
Link: https://doi.org/10.1097/..
 
?
15

P1069: RETROSPECTIVE COMPARISON OF PATIENT OUTCOMES ON PACR..:

Harrison, C. ; Bose, P. ; Mesa, R....
HemaSphere.  6 (2022)  - p. 959-960 , 2022
Link: https://doi.org/10.1097/..
 
1-15